Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program

Impact · against what's priced in

Rocket Pharmaceuticals shows significant asymmetric upside based on a valuation gap between its current enterprise value and the risk-adjusted DCF of its pipeline. The potential for LAD-1 approval in March 2026 and the resumption of the Danon's disease trial with a safer protocol serve as primary catalysts.

RCKT+0.70

No priced-in read yet